A soggy spring day didn’t keep team Johnson & Johnson from training for Philadelphia’s Tour De Cure. For these riders it’s more than just a race, they’re pedaling to fight diabetes. Johnson & Johnson sponsors Tour De Cure nationally, which supports the American Diabetes Association. I met several members of the team at the company’s Spring House campus to find out learn more about the cause and Johnson & Johnson’s long-standing legacy in diabetes care.
It’s the fifth year Charlie Hendrixson with Animas is riding in the premiere bike race, but this year the event especially hits home for him after recently losing the former team captain, Luis Juan, to cancer. I spoke with Luis last year for an Eye Opener segment just before his last Tour De Cure. Luis had diabetes and was one of the team’s biggest fundraisers.
Johnson & Johnson is the biggest corporate sponsor for Philadelphia’s Tour De Cure and this year the goal is to raise half of a million dollars.
In addition, the company produces various products for diabetics. Janssen Pharmaceuticals, Inc. recently introduced INVOKANA(canagliflozin), the company’s first-ever medication to help adults with type 2 diabetes control their glucose levels. The Global Therapeutic Head of Cardiovascular & Metabolism for Janssen Research & Development, Peter DiBattiste, M.D., explained how INVOKANA contributes to the longstanding Johnson & Johnson legacy in diabetes care, stating: “INVOKANA is an important addition to the comprehensive platform of offerings for patients with diabetes from the Johnson & Johnson Family of Companies. These include blood glucose monitoring devices from LifeScan, insulin delivery with Animas, consumer nutritionals such as SPLENDA, among others. We are proud of our ability as an integrated health care company to help improve the lives of people with diabetes.”
The Tour De Cure takes place June 1, 2013. Johnson & Johnson invites you to join them.
By: Ashley Johnson @AshleyNJohnson3